Arkolith/Insider Trading/IGC/Form 4

Mukunda Ram

CEO, DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Mar 18, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
15
7 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2024Option exercise(M)251K—$03.7M
Mar 13, 2024Option exercise(M)17K—$0811K
Mar 13, 2024Option exercise(M)17K—$0794K
Mar 13, 2024Gift(G)200K—$03.5M
Mar 13, 2024Option exercise(M)333K—$03.5M
Mar 13, 2024Option exercise(M)233K—$03.1M
Mar 13, 2024Option exercise(M)333K—$02.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 13, 2024Grant(A)1.5M—$00
Mar 13, 2024Option exercise(M)251K—$0784K
Mar 13, 2024Option exercise(M)333K—$0667K
Mar 13, 2024Option exercise(M)333K—$00
Mar 13, 2024Option exercise(M)233K—$0233K
Mar 13, 2024Option exercise(M)17K—$033K
Mar 13, 2024Grant(A)1.0M—$00
Mar 13, 2024Option exercise(M)17K—$00

Transaction Codes

M
Option exercise / conversion
G
Gift
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-24-000267) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML